OS1.5 Harnessing soluble LRIG1 for pan-RTK targeting in glioblastoma
Abstract
The role of receptor tyrosine kinases (RTKs) in glioblastoma is widely acknowledged. However, therapies based on RTK targeting have been continuously unsuccessful in GBM patients, highlighting the complexity of RTK signaling and biology. LRIG1 (Leucine-rich Repeats and ImmunoGlobulin domains protein 1) was identified as an endogenous inhibitor of epidermal growth factor receptor (EGFR) and other RTKs, and was confirmed as a tumor suppressor in...
Paper Details
Title
OS1.5 Harnessing soluble LRIG1 for pan-RTK targeting in glioblastoma
Published Date
Sep 1, 2018
Journal
Volume
20
Issue
suppl_3
Pages
iii218 - iii218
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History